

Molecular Mechanisms of Targeted Treatments for Solid Tumours

Virtual study day

Thursday 9 December 2021

Aims:

Over the course of the morning, experienced cancer educator Dr Elaine Vickers guides you through the scientific concepts that underpin many of the most used targeted cancer treatments for solid tumours.

Beginning with the bigger picture – what we can and can't target – she describes the mechanisms of action of the two main types of treatment: monoclonal antibodies that target cell surface proteins, and small molecules that block kinases. Many of these treatments target over-active, growth factor-controlled signalling pathways.

Elaine will explain the function of these pathways in healthy cells and their defects in cancer cells. She'll also describe why blocking these pathways sometimes works, and sometimes doesn't. Lastly, Elaine turns her attention to other targets and to various biomarker tests to select the right approach for each patient.

As ever, Elaine's presentations are full of colourful and enlightening illustrations to help learners make sense of scientific concepts. Elaine's descriptions avoid unnecessary jargon and are pitched so that even those with a limited understanding of cell biology are able to understand.

This morning is the first part of a virtual study day. On Friday 10 December it is followed by "Molecular Mechanisms of Immunotherapies for Solid Tumours".

Audience:

This content is ideal for research nurses, clinical nurse specialists, pharmacists and clinical trials coordinators. It may also be of interest to other healthcare professionals involved in the diagnosis and treatment of people with solid tumours, and to junior doctors.

Cost:

£50 per day

Register:

www.royalmarsden.nhs.uk/studydays



Get in touch:

Conferenceteam@rmh.nhs.uk

020 7808 2921

Follow us:



Provisional Programme- Day 1:

10:00 Welcome and Introductions

10:10 Session 1—Targeted Cancer Treatments – the current landscape

- Hallmarks of cancer cells – which can we target?
- The pros and cons of small molecule kinase inhibitors and monoclonal antibodies
- When they work, and when they don't

10:45 Live Q&A

10:55 Break/Sponsor Exhibition

11:00 Session 2—Targeting Cell Communication Pathways

- Targeting growth factor receptors: EGFR, HER2, MET
- Inhibitors of growth factor receptor fusion proteins: ALK, ROS1, RET, TRKA/B/C
- B-Raf & MEK inhibitors
- PI3K & mTOR inhibitors

11:35 Live Q&A

11:45 Break/Sponsor Exhibition

11:50 Session 3—Other Targets and Treatments

- Angiogenesis inhibitors
- PARP inhibitors
- CDK inhibitors
- Biomarkers of response and resistance

12:25 Live Q&A

Please note that the content will be available online for 30 days after the event.